BRAF exon 15 mutations in pediatric renal stromal tumors: prevalence in metanephric stromal tumors

Lily Marsden, Lawrence J Jennings, Samantha L Gadd, Min Yu, Elizabeth J Perlman, Mariana Morais Cajaiba*

*Corresponding author for this work

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Metanephric stromal tumors (MSTs) are rare renal stromal tumors that predominantly affect children. They belong to the metanephric family of tumors, along with metanephric adenofibroma and metanephric adenoma. The previous documentation of BRAF exon 15 mutations in 88% of metanephric adenomas and in isolated cases of metanephric adenofibroma prompted us to investigate the prevalence of these mutations in MSTs and in other pediatric renal stromal tumors. In this study, 17 MSTs, 22 congenital mesoblastic nephromas, and 6 ossifying renal tumors of infancy were selected for BRAF exon 15 testing. Tumor genomic DNA was extracted from formalin-fixed paraffin-embedded tissue, followed by polymerase chain reaction amplification and Sanger dideoxy sequencing with primers flanking the BRAF exon 15 gene. BRAF exon 15 mutations were found in 11 (65%) of the 17 cases of MST, all corresponding to a thymidine-to-adenine substitution at codon 600 (BRAF V600E). All other renal stromal tumors tested were negative for BRAF exon 15 mutations. In conclusion, BRAF V600E mutations are encountered in most MSTs, supporting a link with other metanephric tumors and suggesting a clonal event possibly affecting primordial renal cells. In addition, BRAF V600E mutations have been associated with oncogene-induced senescence in other benign tumors, providing clues to the pathogenesis of metanephric neoplasms in keeping with their overall benign behavior. Our results also suggest a potential diagnostic use for BRAF exon 15 mutations in differentiating MSTs from other pediatric renal stromal tumors, particularly in limited samples.

Original languageEnglish (US)
Pages (from-to)32-36
Number of pages5
JournalHuman pathology
Volume60
DOIs
StatePublished - Feb 1 2017

Fingerprint

Exons
Pediatrics
Kidney
Mutation
Neoplasms
Adenofibroma
Adenoma
Mesoblastic Nephroma
Adenine
Oncogenes
Codon
Documentation
Paraffin
Thymidine
Formaldehyde

Keywords

  • BRAF gene
  • Congenital mesoblastic nephroma
  • Metanephric stromal tumor
  • Ossifying renal tumor of infancy
  • Pediatric renal tumors

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{c5eb8505317048e8a73b28c2d8d19be0,
title = "BRAF exon 15 mutations in pediatric renal stromal tumors: prevalence in metanephric stromal tumors",
abstract = "Metanephric stromal tumors (MSTs) are rare renal stromal tumors that predominantly affect children. They belong to the metanephric family of tumors, along with metanephric adenofibroma and metanephric adenoma. The previous documentation of BRAF exon 15 mutations in 88{\%} of metanephric adenomas and in isolated cases of metanephric adenofibroma prompted us to investigate the prevalence of these mutations in MSTs and in other pediatric renal stromal tumors. In this study, 17 MSTs, 22 congenital mesoblastic nephromas, and 6 ossifying renal tumors of infancy were selected for BRAF exon 15 testing. Tumor genomic DNA was extracted from formalin-fixed paraffin-embedded tissue, followed by polymerase chain reaction amplification and Sanger dideoxy sequencing with primers flanking the BRAF exon 15 gene. BRAF exon 15 mutations were found in 11 (65{\%}) of the 17 cases of MST, all corresponding to a thymidine-to-adenine substitution at codon 600 (BRAF V600E). All other renal stromal tumors tested were negative for BRAF exon 15 mutations. In conclusion, BRAF V600E mutations are encountered in most MSTs, supporting a link with other metanephric tumors and suggesting a clonal event possibly affecting primordial renal cells. In addition, BRAF V600E mutations have been associated with oncogene-induced senescence in other benign tumors, providing clues to the pathogenesis of metanephric neoplasms in keeping with their overall benign behavior. Our results also suggest a potential diagnostic use for BRAF exon 15 mutations in differentiating MSTs from other pediatric renal stromal tumors, particularly in limited samples.",
keywords = "BRAF gene, Congenital mesoblastic nephroma, Metanephric stromal tumor, Ossifying renal tumor of infancy, Pediatric renal tumors",
author = "Lily Marsden and Jennings, {Lawrence J} and Gadd, {Samantha L} and Min Yu and Perlman, {Elizabeth J} and Cajaiba, {Mariana Morais}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.humpath.2016.09.025",
language = "English (US)",
volume = "60",
pages = "32--36",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",

}

BRAF exon 15 mutations in pediatric renal stromal tumors : prevalence in metanephric stromal tumors. / Marsden, Lily; Jennings, Lawrence J; Gadd, Samantha L; Yu, Min; Perlman, Elizabeth J; Cajaiba, Mariana Morais.

In: Human pathology, Vol. 60, 01.02.2017, p. 32-36.

Research output: Contribution to journalArticle

TY - JOUR

T1 - BRAF exon 15 mutations in pediatric renal stromal tumors

T2 - prevalence in metanephric stromal tumors

AU - Marsden, Lily

AU - Jennings, Lawrence J

AU - Gadd, Samantha L

AU - Yu, Min

AU - Perlman, Elizabeth J

AU - Cajaiba, Mariana Morais

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Metanephric stromal tumors (MSTs) are rare renal stromal tumors that predominantly affect children. They belong to the metanephric family of tumors, along with metanephric adenofibroma and metanephric adenoma. The previous documentation of BRAF exon 15 mutations in 88% of metanephric adenomas and in isolated cases of metanephric adenofibroma prompted us to investigate the prevalence of these mutations in MSTs and in other pediatric renal stromal tumors. In this study, 17 MSTs, 22 congenital mesoblastic nephromas, and 6 ossifying renal tumors of infancy were selected for BRAF exon 15 testing. Tumor genomic DNA was extracted from formalin-fixed paraffin-embedded tissue, followed by polymerase chain reaction amplification and Sanger dideoxy sequencing with primers flanking the BRAF exon 15 gene. BRAF exon 15 mutations were found in 11 (65%) of the 17 cases of MST, all corresponding to a thymidine-to-adenine substitution at codon 600 (BRAF V600E). All other renal stromal tumors tested were negative for BRAF exon 15 mutations. In conclusion, BRAF V600E mutations are encountered in most MSTs, supporting a link with other metanephric tumors and suggesting a clonal event possibly affecting primordial renal cells. In addition, BRAF V600E mutations have been associated with oncogene-induced senescence in other benign tumors, providing clues to the pathogenesis of metanephric neoplasms in keeping with their overall benign behavior. Our results also suggest a potential diagnostic use for BRAF exon 15 mutations in differentiating MSTs from other pediatric renal stromal tumors, particularly in limited samples.

AB - Metanephric stromal tumors (MSTs) are rare renal stromal tumors that predominantly affect children. They belong to the metanephric family of tumors, along with metanephric adenofibroma and metanephric adenoma. The previous documentation of BRAF exon 15 mutations in 88% of metanephric adenomas and in isolated cases of metanephric adenofibroma prompted us to investigate the prevalence of these mutations in MSTs and in other pediatric renal stromal tumors. In this study, 17 MSTs, 22 congenital mesoblastic nephromas, and 6 ossifying renal tumors of infancy were selected for BRAF exon 15 testing. Tumor genomic DNA was extracted from formalin-fixed paraffin-embedded tissue, followed by polymerase chain reaction amplification and Sanger dideoxy sequencing with primers flanking the BRAF exon 15 gene. BRAF exon 15 mutations were found in 11 (65%) of the 17 cases of MST, all corresponding to a thymidine-to-adenine substitution at codon 600 (BRAF V600E). All other renal stromal tumors tested were negative for BRAF exon 15 mutations. In conclusion, BRAF V600E mutations are encountered in most MSTs, supporting a link with other metanephric tumors and suggesting a clonal event possibly affecting primordial renal cells. In addition, BRAF V600E mutations have been associated with oncogene-induced senescence in other benign tumors, providing clues to the pathogenesis of metanephric neoplasms in keeping with their overall benign behavior. Our results also suggest a potential diagnostic use for BRAF exon 15 mutations in differentiating MSTs from other pediatric renal stromal tumors, particularly in limited samples.

KW - BRAF gene

KW - Congenital mesoblastic nephroma

KW - Metanephric stromal tumor

KW - Ossifying renal tumor of infancy

KW - Pediatric renal tumors

UR - http://www.scopus.com/inward/record.url?scp=84998892201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998892201&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2016.09.025

DO - 10.1016/j.humpath.2016.09.025

M3 - Article

C2 - 27769870

AN - SCOPUS:84998892201

VL - 60

SP - 32

EP - 36

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

ER -